Moderna (MRNA) has issued an announcement.
Moderna, Inc. has announced significant changes to its Board of Directors. Robert Langer and Stephen Berenson will resign from their board positions effective August 5, 2024, but they will continue to provide consulting services to the company until November 1, 2026. David M. Rubenstein, co-founder of The Carlyle Group Inc., will join the Board on the same date, bringing his expertise to the Audit Committee and serving as a Class III director until the 2027 annual meeting. The company has confirmed that these board movements involve no internal disagreements or undisclosed financial arrangements.
For detailed information about MRNA stock, go to TipRanks’ Stock Analysis page.
